



## OmniPod Guideline

### OMNIPOD (ALL RX PRODUCTS)

**May be approved when the following criteria are met:**

- The member is currently established on therapy with an insulin pump
- The member has a documented frequency of glucose self-testing on average of at least 4 times per day OR is using a continuous glucose monitor (CGM)

**OR**

- The diabetes is being managed with multiple daily insulin injections (at least 3 injections per day) with frequent self-adjustments of the insulin dose for at least 6 months
- Member has a documented frequency of glucose self-testing on average of at least 4 times per day for the past two months OR the member has been using a continuous glucose monitor (CGM) for the past two months
- A comprehensive diabetes education program has been completed
- The member has experienced any of the following while on multiple daily injections of insulin (more than 3 injections per day):
  - Elevated glycosylated hemoglobin level (for example HbA1c greater than 7 percent)
  - History of recurrent hypoglycemia (for example, blood glucose levels less than 70 mg/dL)
  - Wide fluctuations in blood glucose before mealtime
  - Dawn phenomenon with fasting blood sugars frequently exceeding 200 mg/dL
  - History of severe glycemic excursions

**Duration of Approval if Requirements Are Met:**

**Approval Duration:**

12 month

**Quantity Level Limit:**

**Omnipod starter kit:**

1 kit/365 days

**Omnipod pod refills:**

10 pods/30 days

**OmniPod References**

1. Omnipod. 510(k) Premarket Notification FDA Home Medical Devices Databases. Available at: [https://www.accessdata.fda.gov/cdrh\\_docs/pdf19/K192659.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192659.pdf). Accessed September 10, 2021.
2. American Diabetes Association. Standards of Medical Care in Diabetes-2021: Diabetes Care January 2021;42(Supplement1): S1-S2.

Previous Version Effective: 2/4/2019, 3/1/2019, 4/1/2019, 6/3/2019, 6/17/2019, 8/1/2019, 9/9/2019, 10/1/2019, 12/2/2019, 1/1/2020, 1/15/2020, 4/28/2020, 6/8/2020, 8/3/2020, 8/18/2020, 9/1/2020, 10/1/2020, 10/16/2020, 12/1/2020, 3/1/2021, 6/28/2021, 8/1/2021, 8/13/2021, 9/13/2021, 10/1/2021, 10/19/2021, 11/10/2021, 11/25/2021, 1/9/2022, 1/28/2022, 3/25/2022, 4.1.2022, 5/2/2022, 6.7.2022, 6.9.2022, 6.29.2022, 8.1.2022, 8.23.2022, 9.6.2022

Current Version Effective: 10.1.2022



3. McAdams BH, Rizvi AA. An Overview of Insulin Pumps and Glucose Sensors for the Generalist. *J Clinical Medicine* 2016;5;1-17.
4. Peters AL, Ahmann AJ, Battelino T et al. Diabetes Technology – Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 2016; 101(11):3922-3937.
5. Grunberger G, Abelseth JM, Baily TS et al. Consensus statement by the American Association of Clinical Endocrinologist/American College of Endocrinology Insulin Pump Management Task Force. *Endocr Pract.* 204;20(No 5):463-489.
6. National Coverage Determination (NCD) for Infusion Pumps (280.14); Revision Effective Date 12/17/2004; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=223&ncdver=2&NCAId=41&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=BC%7cSAD%7cRTC%7cReg&PolicyType=Both&s=47&Keyword=INSULIN+PUMP&KeywordLookUp=Title&KeywordSearchType=Exact&kq=true&bc=EAAAABAAIAAA&>. Accessed September 10, 2021.
7. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res.* 2012;64(10):1431-1446.
8. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis.* 2017;76:29-42.
9. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. *Arthritis Care Res.* 2012;64(10):1447-1461.
10. Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology Guideline for the Management of Gout. *Rheumatology.* 2017;56(7):e1–e20. Available at <https://doi.org/10.1093/rheumatology/kex156>
11. Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systemic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. *Ann Rheum Dis.* 2014;73(2):328-335.
12. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout [published correction appears in *Arthritis Care Res (Hoboken)*. 2020 Aug;72(8):1187]. *Arthritis Care Res (Hoboken)*. 2020;72(6):744-760.

Previous Version Effective: 2/4/2019, 3/1/2019, 4/1/2019, 6/3/2019, 6/17/2019, 8/1/2019, 9/9/2019, 10/1/2019, 12/2/2019, 1/1/2020, 1/15/2020, 4/28/2020, 6/8/2020, 8/3/2020, 8/18/2020, 9/1/2020, 10/1/2020, 10/16/2020, 12/1/2020, 3/1/2021, 6/28/2021, 8/1/2021, 8/13/2021, 9/13/2021, 10/1/2021, 10/19/2021, 11/10/2021, 11/25/2021, 1/9/2022, 1/28/2022, 3/25/2022, 4.1.2022, 5/2/2022, 6.7.2022, 6.9.2022, 6.29.2022, 8.1.2022, 8.23.2022, 9.6.2022  
Current Version Effective: 10.1.2022